Premium
Asiatic acid, a pentacyclic triterpene from Centella asiatica , is neuroprotective in a mouse model of focal cerebral ischemia
Author(s) -
Krishnamurthy Rajanikant G.,
Senut MarieClaude,
Zemke Daniel,
Min Jiangyong,
Frenkel Mark B.,
Greenberg Eric J.,
Yu SeongWoon,
Ahn Nick,
Goudreau John,
Kassab Mounzer,
Panickar Kiran S.,
Majid Arshad
Publication year - 2009
Publication title -
journal of neuroscience research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.72
H-Index - 160
eISSN - 1097-4547
pISSN - 0360-4012
DOI - 10.1002/jnr.22071
Subject(s) - centella , triterpene , neuroprotection , ischemia , pharmacology , traditional medicine , chemistry , medicine , pathology , alternative medicine
Asiatic acid, a triterpenoid derivative from Centella asiatica , has shown biological effects such as antioxidant, antiinflammatory, and protection against glutamate‐ or β‐amyloid‐induced neurotoxicity. We investigated the neuroprotective effect of asiatic acid in a mouse model of permanent cerebral ischemia. Various doses of asiatic acid (30, 75, or 165 mg/kg) were administered orally at 1 hr pre‐ and 3, 10, and 20 hr postischemia, and infarct volume and behavioral deficits were evaluated at day 1 or 7 postischemia. IgG (blood–brain barrier integrity) and cytochrome c (apoptosis) immunostaining was carried out at 24 hr postischemia. The effect of asiatic acid on stress‐induced cytochrome c release was examined in isolated mitochondrial fractions. Furthermore, its effects on cell viability and mitochondrial membrane potential were studied in HT‐22 cells exposed to oxygen‐glucose deprivation. Asiatic acid significantly reduced the infarct volume by 60% at day 1 and by 26% at day 7 postischemia and improved neurological outcome at 24 hr postischemia. Our studies also showed that the neuroprotective properties of asiatic acid might be mediated in part through decreased blood–brain barrier permeability and reduction in mitochondrial injury. The present study suggests that asiatic acid may be useful in the treatment of cerebral ischemia. © 2009 Wiley‐Liss, Inc.